Intra-articular Injections of Platelet-rich Plasma, Hyaluronic Acid, or Corticosteroids for Knee Osteoarthritis

University of Wasit

Status and phase: Unknown; Phase 3

Conditions: Osteoarthritis, Knee

Treatments: Drug: Hyaluronic acid; Drug: Methylprednisolone acetate injectable suspension (DEPO-MEDROL®); Biological: Platelet-rich plasma

Study type: Interventional

Funder types: Other

Identifiers

NCT04980105

UOW/MS102

Details and patient eligibility

About

To assess if there are any differences among platelet-rich plasma, hyaluronic acid, and corticosteroid knee intra-articular injection regarding function and pain.

Enrollment: 150 patients

Sex: All

Ages: 35 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient aged 35-65 years old
• Patient with knee pain that had been continuing for at least 12 months with no relief using anti-inflammatory medications and that deteriorated with weight-bearing
• Knee osteoarthritis that classified as mild-moderate or moderate-severe (Kellgren-Lawrence Grade 2, 3, or 4)

Exclusion criteria

• Age > 65 years
• The recent history of knee trauma
• Autoimmune rheumatic diseases
• Accompanying severe hip OA
• Thrombocytopenia or other blood diseases
• Immunosuppressive or anticoagulant treatment
• The invasive procedure applied to the knee
• Intra-articular steroid injection to the knee within the previous 12 months
• Previous joint infection
• Uncontrolled systemic diseases such as diabetes or hypertension, and cancer
• Excessive varus/valgus knee deformity

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

150 participants in 3 patient groups

Platelet-rich plasma arm

Experimental group

Treatment:

Biological: Platelet-rich plasma

Hyaluronic acid arm

Active Comparator group

Treatment:

Drug: Hyaluronic acid

Methylprednisolone acetate arm

Active Comparator group

Treatment:

Drug: Methylprednisolone acetate injectable suspension (DEPO-MEDROL®)